Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 154 for “"mycn"”.

  1. Role of MYCN in Prostate Cancer

    … et al., 2007; Zhu et al., 2021). The oncogene MYCN – known to play a central role in many cancers – is overexpressed in the NEPC subtype (J. K. Lee et al., 2016). Unfortunately, MYCN itself is considered “undruggable” (Wolpaw et al., 2021). However, MYCN is known to interact with partner …

    wurz-thes Repository record for Role of MYCN in Prostate Cancer (opens in a new tab)

  2. The MYCN locus as an integrated oncogenic unit: noncoding mechanisms and improved modeling of MYCN-amplified neuroblastoma

    … of pediatric cancer deaths. Amplification of MYCN is one of the strongest predictors of aggressive disease, rapid progression, and poor clinical outcome. Despite decades of research, experimental models of MYCN-driven neuroblastoma have focused predominantly on MYCN protein function and have …

    texas Repository record for The MYCN locus as an integrated oncogenic unit: noncoding mechanisms and improved modeling of MYCN-amplified neuroblastoma (opens in a new tab)

  3. Therapeutically targeting USP5 in MYCN-driven neuroblastoma

    Advanced neuroblastoma is associated with MYCN amplification and gene amplification of MYCN has been shown to correlate with poor prognosis in patients. The MYC family of proteins have been widely researched due to their important roles in the development of various cancers including neuroblastoma. …

    unsw Repository record for Therapeutically targeting USP5 in MYCN-driven neuroblastoma (opens in a new tab)

  4. Epigenetic regulators contributing to MYCN-driven neuroblastoma

    … showed significant anti-cancer efficacy against MYCN-amplified neuroblastoma both in vitro and in vivo. The combination therapy also synergistically reduced the expression of key oncogenic genes such as Bcl-2, LIN28B and N-Myc with minimum cytotoxicity on normal human fibroblast cells In …

    unsw Repository record for Epigenetic regulators contributing to MYCN-driven neuroblastoma (opens in a new tab)

  5. Charakterisierung von Retinoblastomen mit Amplifikation des Onkogens MYCN

    Amplification of the oncogene MYCN has been described in a minority of retinoblastomas with and without RB1 inactivation. It is assumed that MYCN amplified retinoblastomas are associated with a more aggressive clinical behavior and an unfavorable prognosis. In this dissertation, the incidence, RB1 …

    greece Repository record for Charakterisierung von Retinoblastomen mit Amplifikation des Onkogens MYCN (opens in a new tab)

  6. MYCN is an RNA binding protein mediating transcript decay

    The MYCN oncoprotein is frequently overexpressed in neuroblastoma, where it acts as a major driver of tumorigenesis. MYCN is a transcription factor that regulates gene expression through widespread promoter binding. However, the overall impact of MYCN on transcriptional output is modest, suggesting …

    wurz-thes Repository record for MYCN is an RNA binding protein mediating transcript decay (opens in a new tab)

  7. Analysis of MYCN and MAX alterations in Wilms Tumor

    … common renal tumor in childhood. Among others, MYCN copy number gain and MYCN P44L and MAX R60Q mutations have been identified in WT. The proto-oncogene MYCN encodes a transcription factor that requires dimerization with MAX to activate transcription of numerous target genes. MYCN gain has been …

    wurz-thes Repository record for Analysis of MYCN and MAX alterations in Wilms Tumor (opens in a new tab)

  8. Downregulation of MYCN oncogene by retinoic acid in neuroblastoma

    … tumors show the gene amplification of MYCN oncogene. Because MYCN plays a critical role, MYCN gene amplification is considered an important risk factor of neuroblastoma. Retinoic acid (RA) is one of the few agents which can improve the survival rate of patients in the high risk group. …

    hawaii Repository record for Downregulation of MYCN oncogene by retinoic acid in neuroblastoma (opens in a new tab)

  9. Die Telomerlänge als Prognosefaktor in MYCN nicht-amplifizierten Neuroblastomen

    … Beispiel Alter bei Erstdiagnose, Tumorstadium, MYCN-Amplifikation und 1p Deletion, werden seit längerem zur Risikostratifizierung genutzt. Bereits in anderen Tumorerkrankungen konnte nun der Einfluß einer Telomerlängenveränderung auf das Gesamtüberleben von Patienten nachgewiesen werden. …

    qucosa-diss

  10. Development of MYCN inhibitors to treat high-risk neuroblastoma

    … 50% chance of survival and experience relapse. MYCN is an oncogene belongs to the MYC family and is a major oncogenic driver of NB. Direct targeting MYCN has been challenging due to its structure with no deep pocket for direct binding of small molecules. Alternatively, indirectly targeting MYCN …

    unsw Repository record for Development of MYCN inhibitors to treat high-risk neuroblastoma (opens in a new tab) Embargoed

  11. Aurora-A prevents transcription-replication conflicts in MYCN-amplified neuroblastoma

    … Patients with high-risk neuroblastoma often show MYCN-amplification and elevated levels of Aurora-A. They have a low overall survival and despite multimodal therapy options a poor therapeutic prognosis. MYCN-amplified neuroblastoma cells depend on Aurora-A functionality. Aurora-A stabilizes MYCN …

    wurz-thes Repository record for Aurora-A prevents transcription-replication conflicts in MYCN-amplified neuroblastoma (opens in a new tab)

  12. Investigating Inhibition of MYCN in the Treatment of Wilms' Tumour

    … Tumour subtype has displayed a greater level of MYCN expression, a known oncoprotein, and while genetic alteration of MYCN has been reported, no biological functional studies have been conducted. Here I have shown that MYCN depletion via small interfering RNA results in growth suppression whereas …

    bristol Repository record for Investigating Inhibition of MYCN in the Treatment of Wilms' Tumour (opens in a new tab) Download PDF for Investigating Inhibition of MYCN in the Treatment of Wilms' Tumour (opens in a new tab)

  13. G9a as a potential therapeutic target in MYCN-amplified neuroblastomas

    MYCN-amplification is a high-risk factor in neuroblastoma which contributes to a poor prognostic outcome. Here data is presented showing that both short-interfering RNA depletion and treatment by small molecule inhibitors (SMI) of lysine-specific histone methyltransferase Euchromatic Histone Lysine …

    bristol Repository record for G9a as a potential therapeutic target in MYCN-amplified neuroblastomas (opens in a new tab) Download PDF for G9a as a potential therapeutic target in MYCN-amplified neuroblastomas (opens in a new tab)

  14. MYCN amplification in neuroblastoma: sequence, chromatin landscape, and genome remodeling

    MYCN amplification drives half of all high-risk neuroblastomas and confers dismal prognosis. It occurs when MYCN and other chromosomal fragments are joined together to form an amplicon sequence that can be found tens to hundreds of times per cell. In most cases, these copies come as …

    fu-berlin Repository record for MYCN amplification in neuroblastoma: sequence, chromatin landscape, and genome remodeling (opens in a new tab)

  15. From MYCN to inflammaging : understanding the pathogenesis of immature T-ALL

    … T cells (Late). Early leukemias exhibited high MYCN expression, which correlated with poor clinical outcome in a large pediatric cohort. Knockout and knockdown experiments revealed Early leukemias to be dependent on MYCN for initial transformation and subsequent clonal propagation. Use of …

    ubc Repository record for From MYCN to inflammaging : understanding the pathogenesis of immature T-ALL (opens in a new tab) Download PDF for From MYCN to inflammaging : understanding the pathogenesis of immature T-ALL (opens in a new tab)

  16. Inhibition von Aurora-A als neue Therapiestrategie gegen MYCN-amplifizierte Neuroblastome

    Im Neuroblastom ist die Amplifikation des MYCN-Gens, das für den Transkriptionsfaktor N-Myc kodiert, der klinisch bedeutendste Faktor für eine schlechte Prognose. Als Mitglied der onkogenen Myc-Familie induziert N-Myc die Expression von Genen, die in vielen biologischen Prozessen wie Metabolismus, …

    wurz-thes Repository record for Inhibition von Aurora-A als neue Therapiestrategie gegen MYCN-amplifizierte Neuroblastome (opens in a new tab)

  17. INHIBITION MYCN- VERMITTELTER ZELLZYKLUSTRANSITION DURCH THYROID CANCER 1 (TC1) IM NEUROBLASTOM – ETABLIERUNG UND CHARAKTERISIERUNG DES TC1- ÜBEREXPRESSIONSPHÄNOTYPS IN HUMANEN SH-EP NEUROBLASTOMZELLEN UNTER DEM EINFLUSS VON MYCN

    … die Amplifikation und erhöhte Expression von MYCN dar. In Vorarbeiten der Arbeitsgruppe von Prof. Christiansen zeigte MYCN Einfluss auf die Genregion von Thyroid Cancer 1 (TC1), das als neuer Marker für maligne Schilddrüsenkarzinome erkannt wurde. In der vorliegenden Arbeit wurden erste …

    qucosa-diss

Page 1 of 8